Nuplazid Eases Depression in Parkinson’s Patients, Phase 2 Trial Shows

Nuplazid Eases Depression in Parkinson’s Patients, Phase 2 Trial Shows
Treatment with Nuplazid (pimavanserin), approved in the U.S. for treating hallucinations and delusions associated with Parkinson’s psychosis, eased depression and sleep problems in patients with Parkinson’s, according to results from a Phase 2 clinical trial. The research, “Open-Label Study of Pimavanserin Patients With Comorbid Parkinson’s Disease and Depression,” was presented at the 2019 International Congress of Parkinson’s Disease and Movement Disorders in Nice, ... read more
Source: Parkinson’s News TodayPublished on 2019-10-01By Jose Marques Lopes, PhD